Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 12/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 12/20 | 0.37 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.34 |
| ▸ | PTPRF | P10586 | 1/20 | 0.34 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1749874 | 1.00 | HDAC1 (0.37) | HDAC1HDAC6AVPR1BPTPRFPTPN2 | |
| SCHEMBL1750607 | 0.93 | HDAC1 (0.35) | HDAC1HDAC6 | |
| SCHEMBL1749610 | 0.90 | PPARA (0.42) | PTPRFPTPN2PTPN1 | |
| SCHEMBL1750047 | 0.90 | PPARA (0.42) | PTPRFPTPN2PTPN1 | |
| SCHEMBL1750048 | 0.90 | PPARA (0.42) | PTPRFPTPN2PTPN1 | |
| SCHEMBL1750452 | 0.87 | PPARA (0.43) | PTPRFPTPN2PTPN1 | |
| SCHEMBL1750450 | 0.87 | PPARA (0.43) | PTPRFPTPN2PTPN1 | |
| SCHEMBL1751480 | 0.84 | HTR5A (0.38) | AVPR1BPTPRFPTPN2PTPN1 | |
| SCHEMBL1749560 | 0.83 | PPARA (0.45) | — | |
| SCHEMBL1749558 | 0.83 | PPARA (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8022079-B2 | Methods of modulating PPAR gamma-type receptors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-09-20 | — | — | US | disclosed |
| EP-1638964-B1 | NOVEL COMPOUNDS THAT MODULATE PPAR-GAMMA TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RES & DEV (FR) | 2011-07-27 | — | — | EP | disclosed |
| US-7968560-B2 | Compounds that modulate PPARγ-type receptors and cosmetic/pharmaceutical compositions comprising said compounds | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-06-28 | — | — | US | disclosed |
| US-20100247468-A1 | Compounds that modulate PPAR gamma-type receptors and cosmetic/pharmaceutical compositions comprising said compounds | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-09-30 | — | — | US | disclosed |
| US-20100099689-A1 | METHODS OF MODULATING PPAR GAMMA-TYPE RECEPTORS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-04-22 | — | — | US | disclosed |
| US-7625914-B2 | Compounds that modulate PPARγ type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-12-01 | — | — | US | disclosed |
| US-20060148862-A1 | Novel compounds that modulate PPARy type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099689-A1 | METHODS OF MODULATING PPAR GAMMA-TYPE RECEPTORS | PPARG, PPARA, PPARD | HDAC1 443/4885HDAC6 858/4885AVPR1B 1887/4885 |
| US-20060148862-A1 | Novel compounds that modulate PPARy type receptors and cosmetic/pharmaceutical compositions comprised thereof | PPARG, PPARD, PPARA | HDAC1 755/4885HDAC6 1213/4885AVPR1B 1553/4885 |
| US-20100247468-A1 | Compounds that modulate PPAR gamma-type receptors and cosmetic/pharmaceutical compositions comprising said compounds | PPARG, PPARD, PPARA | HDAC1 477/4885HDAC6 1035/4885AVPR1B 1668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.